Shufang Du
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shufang Du has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Sijia Hu
State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Department of Orthodontics, West China Hospital of Stomatology, Sichuan University, China
2 shared publicationsBingxue Du
State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, Department of Orthodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China
1 shared publicationChaoran Xue
State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Orthodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China
1 shared publication- Chenyu Chu
Department of Oral Implantology & State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China
1 shared publication Chongying Su
State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Department of Orthodontics, West China Hospital of Stomatology, Sichuan University, China
1 shared publicationDan Mei
State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology Department of Orthodontics, Sichuan University, Chengdu, 610041, Sichuan, China
1 shared publication
Latest Publications
- Open Access
- 14 November 2025
- Published by Springer Nature in BMC Oral Health
- Vol. 25 (1) , 1783
Anterior arch form-specific analysis of alveolar bone thickness and tooth inclination: associations and clinical relevance in skeletal class II malocclusion
To evaluate the associations among alveolar bone thickness, labio‑palatal tooth inclination, anterior dental arch form, and vertical skeletal pattern in skeletal Class II malocclusion, and to derive anterior arch form–indicated risk predisposition for orthodontic tooth movement. Cone-beam computed tomography (CBCT) scans of 100 skeletal Class II malocclusion patients were grouped into square, ovoid, and tapered arch forms, and were further divided into three vertical skeletal pattern groups. Alveolar bone thickness at three levels (3 mm, 6 mm apical from cementoenamel junction (CEJ), and root apex) on labial and palatal sides of maxillary central incisors, lateral incisors, and canines, as well as labio-palatal inclinations of these teeth, were measured and compared. Two-way analysis of variance (ANOVA) was used to compare the thickness of alveolar bone among nine dental arch form and vertical skeletal pattern groups. Pearson’s correlation test assessed the relationships between bone thickness and tooth inclination. Across eighteen measurement sites, two‑way ANOVA identified an arch‑form main effect at eight sites and a vertical‑pattern main effect at seven sites (P < 0.05). The square group exhibited thicker bone than tapered group on the palatal side of central incisors, as well as the labial side of lateral incisors and canines (P < 0.05), while the tapered group had the thickest bone at labial root apex of central incisors (2.33 mm, P < 0.05). Significant differences in thickness were observed among three vertical skeletal pattern groups at 6 mm apical from CEJ and root apex sites of incisors and canines (P < 0.05). Square group had the smallest incisor inclination (103.09° for central incisors and 104.05° for lateral incisors, P < 0.05), and square group had smaller canine inclination (98.80°) than ovoid group (104.58°, P < 0.05). Significant correlations between bone thickness and tooth inclination were observed in three arch form groups (P < 0.05). Anterior dental arch form associates with alveolar bone thickness and tooth inclination, suggesting its potential to be a rapid, chair‑side preliminary indicator of tooth movement limits in skeletal Class II malocclusion.
- 14 November 2025
- Published by Springer Nature in BMC Oral Health
- Vol. 25 (1) , 1783
Open AccessAnterior arch form-specific analysis of alveolar bone thickness and tooth inclination: associations and clinical relevance in skeletal class II malocclusion
To evaluate the associations among alveolar bone thickness, labio‑palatal tooth inclination, anterior dental arch form, and vertical skeletal pattern in skeletal Class II malocclusion, and to derive anterior arch form–indicated risk predisposition for orthodontic tooth movement. Cone-beam computed tomography (CBCT) scans of 100 skeletal Class II malocclusion patients were grouped into square, ovoid, and tapered arch forms, and were further divided into three vertical skeletal pattern groups. Alveolar bone thickness at three levels (3 mm, 6 mm apical from cementoenamel junction (CEJ), and root apex) on labial and palatal sides of maxillary central incisors, lateral incisors, and canines, as well as labio-palatal inclinations of these teeth, were measured and compared. Two-way analysis of variance (ANOVA) was used to compare the thickness of alveolar bone among nine dental arch form and vertical skeletal pattern groups. Pearson’s correlation test assessed the relationships between bone thickness and tooth inclination. Across eighteen measurement sites, two‑way ANOVA identified an arch‑form main effect at eight sites and a vertical‑pattern main effect at seven sites (P < 0.05). The square group exhibited thicker bone than tapered group on the palatal side of central incisors, as well as the labial side of lateral incisors and canines (P < 0.05), while the tapered group had the thickest bone at labial root apex of central incisors (2.33 mm, P < 0.05). Significant differences in thickness were observed among three vertical skeletal pattern groups at 6 mm apical from CEJ and root apex sites of incisors and canines (P < 0.05). Square group had the smallest incisor inclination (103.09° for central incisors and 104.05° for lateral incisors, P < 0.05), and square group had smaller canine inclination (98.80°) than ovoid group (104.58°, P < 0.05). Significant correlations between bone thickness and tooth inclination were observed in three arch form groups (P < 0.05). Anterior dental arch form associates with alveolar bone thickness and tooth inclination, suggesting its potential to be a rapid, chair‑side preliminary indicator of tooth movement limits in skeletal Class II malocclusion.
- Open Access
- 19 September 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1640090
ADAM17 as a promising therapeutic target: from structural basis to inhibitor discovery in human diseases
A disintegrin and metalloproteinase 17 (ADAM17) is a transmembrane protease that regulates diverse physiological processes by shedding membrane-bound proteins, including cytokines, their receptors, and adhesion molecules. A mounting body of evidence has emerged linking ADAM17 to the pathogenesis of various diseases, including inflammation, cancer, cardiovascular and neurodegenerative diseases, highlighting its potential as a therapeutic target. This review offers a comprehensive overview of the molecular structure and biological functions of ADAM17, emphasizing its role in human diseases and therapeutic strategies that target ADAM17 activity. Recent advances in the development of ADAM17-targeting agents, including small-molecule inhibitors, monoclonal antibodies, and endogenous regulatory proteins, are discussed with a focus on the structural basis of their activity, with the aim of informing and guiding future drug discovery efforts.
- 19 September 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1640090
Open AccessADAM17 as a promising therapeutic target: from structural basis to inhibitor discovery in human diseases
A disintegrin and metalloproteinase 17 (ADAM17) is a transmembrane protease that regulates diverse physiological processes by shedding membrane-bound proteins, including cytokines, their receptors, and adhesion molecules. A mounting body of evidence has emerged linking ADAM17 to the pathogenesis of various diseases, including inflammation, cancer, cardiovascular and neurodegenerative diseases, highlighting its potential as a therapeutic target. This review offers a comprehensive overview of the molecular structure and biological functions of ADAM17, emphasizing its role in human diseases and therapeutic strategies that target ADAM17 activity. Recent advances in the development of ADAM17-targeting agents, including small-molecule inhibitors, monoclonal antibodies, and endogenous regulatory proteins, are discussed with a focus on the structural basis of their activity, with the aim of informing and guiding future drug discovery efforts.
- Open Access
- 25 July 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1556196
CXCR3 inhibitors for therapeutic interventions: current status and perspectives
CXC chemokine receptor 3 (CXCR3) is a G protein-coupled chemokine receptor that plays a key role in regulating immune responses and is involved in various pathological processes, particularly in tumor development and inflammatory diseases, making it a novel target for clinical therapy. The expression of CXCR3 and its ligands—CXCL9, CXCL10, CXCL11, CXCL4, and CXCL4L1—is closely associated with the onset and progression of numerous diseases. With a deeper understanding of the mechanisms underlying CXCR3 function, significant progress has been made in the development of small molecule antagonists targeting CXCR3, some of which have entered clinical trials and demonstrated therapeutic potential. This review provides an overview of the structure and signaling pathways of CXCR3, its biological functions in cancer and inflammatory diseases, and highlights the innovative roles of CXCR3 in these diseases. Furthermore, it discusses recent advances in the development of small molecule antagonists, particularly those that have been tested in clinical settings, such as AMG 487 and ACT-777991. These studies provide a scientific foundation for the development of novel CXCR3 antagonists and may offer new directions for future clinical treatments.
- 25 July 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1556196
Open AccessCXCR3 inhibitors for therapeutic interventions: current status and perspectives
CXC chemokine receptor 3 (CXCR3) is a G protein-coupled chemokine receptor that plays a key role in regulating immune responses and is involved in various pathological processes, particularly in tumor development and inflammatory diseases, making it a novel target for clinical therapy. The expression of CXCR3 and its ligands—CXCL9, CXCL10, CXCL11, CXCL4, and CXCL4L1—is closely associated with the onset and progression of numerous diseases. With a deeper understanding of the mechanisms underlying CXCR3 function, significant progress has been made in the development of small molecule antagonists targeting CXCR3, some of which have entered clinical trials and demonstrated therapeutic potential. This review provides an overview of the structure and signaling pathways of CXCR3, its biological functions in cancer and inflammatory diseases, and highlights the innovative roles of CXCR3 in these diseases. Furthermore, it discusses recent advances in the development of small molecule antagonists, particularly those that have been tested in clinical settings, such as AMG 487 and ACT-777991. These studies provide a scientific foundation for the development of novel CXCR3 antagonists and may offer new directions for future clinical treatments.
- 18 July 2025
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 17 (14) , 1757-1770
Small-molecule Cathepsin K inhibitors: a medicinal chemistry perspective
Cathepsin K (Cat K) is a member of the Cathepsin family and is found in a wide range of tissues. Cat K is involved in the terminal catabolism and recycling of endocytosed proteins, as well as specific cellular processes and a wide range of diseases. It is predominantly expressed in osteoclasts and has potent collagenase activity. Based on its particular structure and biological functions, Cat K inhibitors with precise targeting and good penetration are potential therapeutic approaches for related diseases. In this paper, we introduce the structure and biological functions of Cat K and focus on Cat K inhibitors with therapeutic potential for human diseases.
- 18 July 2025
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 17 (14) , 1757-1770
Small-molecule Cathepsin K inhibitors: a medicinal chemistry perspective
Cathepsin K (Cat K) is a member of the Cathepsin family and is found in a wide range of tissues. Cat K is involved in the terminal catabolism and recycling of endocytosed proteins, as well as specific cellular processes and a wide range of diseases. It is predominantly expressed in osteoclasts and has potent collagenase activity. Based on its particular structure and biological functions, Cat K inhibitors with precise targeting and good penetration are potential therapeutic approaches for related diseases. In this paper, we introduce the structure and biological functions of Cat K and focus on Cat K inhibitors with therapeutic potential for human diseases.
- Open Access
- 1 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-9
Knowledge, attitude, and practice of orthodontic treatment among student patients preparing for or undergoing treatment
This study aimed to investigate the levels of knowledge, attitude and practice (KAP) of orthodontic treatment among student patients either preparing for or actively undergoing orthodontic treatment. This cross-sectional study was conducted at a tertiary dental hospital in southwest China between August, 2023 and February, 2024. Demographic characteristics and KAP scores were collected using a self- reported questionnaire. A total of 431 valid questionnaires were included, with a mean participant age of 15.25 ± 4.47 years. The mean scores for knowledge, attitude, and practice scores were 13.53 ± 5.36 (possible range: 0–22), 28.18 ± 5.17 (possible range: 8–40), and 33.07 ± 6.81 (possible range: 9–45), respectively. Path analysis indicated that knowledge directly influenced attitude (β = 0.22, P < 0.001) and practice (β = 0.47, P < 0.001), while attitude directly influenced practice (β = 0.24, P < 0.001). Knowledge also indirectly influenced practice via attitude (β = 0.05, P < 0.001). Student patients preparing for or undergoing orthodontic treatment demonstrated moderate KAP scores related to the treatment. Efforts should focus on enhancing patient understanding to improve overall KAP scores and optimize orthodontic treatment outcomes.
- 1 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-9
Open AccessKnowledge, attitude, and practice of orthodontic treatment among student patients preparing for or undergoing treatment
This study aimed to investigate the levels of knowledge, attitude and practice (KAP) of orthodontic treatment among student patients either preparing for or actively undergoing orthodontic treatment. This cross-sectional study was conducted at a tertiary dental hospital in southwest China between August, 2023 and February, 2024. Demographic characteristics and KAP scores were collected using a self- reported questionnaire. A total of 431 valid questionnaires were included, with a mean participant age of 15.25 ± 4.47 years. The mean scores for knowledge, attitude, and practice scores were 13.53 ± 5.36 (possible range: 0–22), 28.18 ± 5.17 (possible range: 8–40), and 33.07 ± 6.81 (possible range: 9–45), respectively. Path analysis indicated that knowledge directly influenced attitude (β = 0.22, P < 0.001) and practice (β = 0.47, P < 0.001), while attitude directly influenced practice (β = 0.24, P < 0.001). Knowledge also indirectly influenced practice via attitude (β = 0.05, P < 0.001). Student patients preparing for or undergoing orthodontic treatment demonstrated moderate KAP scores related to the treatment. Efforts should focus on enhancing patient understanding to improve overall KAP scores and optimize orthodontic treatment outcomes.
- 31 July 2024
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 16 (15) , 1561-1582
Dual-target EZH2 inhibitor: latest advances in medicinal chemistry
Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, plays a crucial role in tumor progression by regulating gene expression. EZH2 inhibitors have emerged as promising anti-tumor agents due to their potential in cancer treatment strategies. However, single-target inhibitors often face limitations such as drug resistance and side effects. Dual-target inhibitors, exemplified by EZH1/2 inhibitor HH-2853(28), offer enhanced efficacy and reduced adverse effects. This review highlights recent advancements in dual inhibitors targeting EZH2 and other proteins like BRD4, PARP1, and EHMT2, emphasizing rational design, structure-activity relationships, and safety profiles, suggesting their potential in clinical applications.
- 31 July 2024
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 16 (15) , 1561-1582
Dual-target EZH2 inhibitor: latest advances in medicinal chemistry
Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, plays a crucial role in tumor progression by regulating gene expression. EZH2 inhibitors have emerged as promising anti-tumor agents due to their potential in cancer treatment strategies. However, single-target inhibitors often face limitations such as drug resistance and side effects. Dual-target inhibitors, exemplified by EZH1/2 inhibitor HH-2853(28), offer enhanced efficacy and reduced adverse effects. This review highlights recent advancements in dual inhibitors targeting EZH2 and other proteins like BRD4, PARP1, and EHMT2, emphasizing rational design, structure-activity relationships, and safety profiles, suggesting their potential in clinical applications.